However, promoting ferroptosis in liver cancer cells, suppressing the expression of metallothionein 1G (MT1G) and oxidative stress-related protein sigma 1 receptor (S1R) can both improve the drug resistance of liver cancer to sorafenib (Sun, et al., 2016a). This evidence concerns the gene TMBIM4 and liver cancer.